Tweetable abstract
toxicity
In a pilot study, 15 advanced/recurrent head and neck squamous-cell carcinoma patients will be treated with pembrolizumab plus quad-shot hypofractionated palliative radiotherapy. Response, survival and toxicity will be measured.